Benchmark Co. Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $35
Surgery Partners Price Target Maintained With a $35.00/Share by Benchmark
Surgery Partners Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Surgery Partners (SGRY)
Barclays Maintains Surgery Partners(SGRY.US) With Hold Rating, Cuts Target Price to $25
Surgery Partners (SGRY) Receives a Hold From Barclays
Cantor Fitzgerald Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $36
RBC Capital Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $35
Mizuho Securities Maintains Surgery Partners(SGRY.US) With Buy Rating, Announces Target Price $28
Strong Financial Performance and Strategic Positioning Drive Buy Rating for Surgery Partners
Surgery Partners Analyst Ratings
Macquarie Trims Price Target on Surgery Partners to $33 From $34, Keeps Outperform Rating
RBC Capital Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $35
Surgery Partners (SGRY) Gets a Buy From RBC Capital
TD Cowen Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $28
A Quick Look at Today's Ratings for Surgery Partners(SGRY.US), With a Forecast Between $28 to $36
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), BioLife Solutions (BLFS) and Surgery Partners (SGRY)
Benchmark Co. Maintains Surgery Partners(SGRY.US) With Buy Rating, Cuts Target Price to $35
Cantor Fitzgerald Maintains Surgery Partners(SGRY.US) With Buy Rating, Cuts Target Price to $36
Jefferies Maintains Surgery Partners(SGRY.US) With Buy Rating, Cuts Target Price to $31